Literature DB >> 10430830

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

P Damier1, E C Hirsch, Y Agid, A M Graybiel.   

Abstract

To achieve accuracy in studying the patterns of loss of midbrain dopamine-containing neurons in Parkinson's disease, we used compartmental patterns of calbindin D(28K) immunostaining to subdivide the substantia nigra with landmarks independent of the degenerative process. Within the substantia nigra pars compacta, we identified dopamine-containing neurons in the calbindin-rich regions ('matrix') and in five calbindin-poor pockets ('nigrosomes') defined by analysis of the three-dimensional networks formed by the calbindin-poor zones. These zones were recognizable in all of the brains, despite severe loss of dopamine-containing neurons. The degree of loss of dopamine-containing neurons in the substantia nigra pars compacta was related to the duration of the disease, and the cell loss followed a strict order. The degree of neuronal loss was significantly higher in the nigrosomes than in the matrix. Depletion was maximum (98%) in the main pocket (nigrosome 1), located in the caudal and mediolateral part of the substantia nigra pars compacta. Progressively less cell loss was detectable in more medial and more rostral nigrosomes, following the stereotyped order of nigrosome 1 > nigrosome 2 > nigrosome 4 > nigrosome 3 > nigrosome 5. A parallel, but lesser, caudorostral gradient of cell loss was observed for dopamine-containing neurons included in the matrix. This pattern of neuronal loss was consistent from one parkinsonian substantia nigra pars compacta to another. The spatiotemporal progression of neuronal loss related to disease duration can thus be drawn in the substantia nigra pars compacta for each Parkinson's disease patient: depletion begins in the main pocket (nigrosome 1) and then spreads to other nigrosomes and the matrix along rostral, medial and dorsal axes of progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430830     DOI: 10.1093/brain/122.8.1437

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  446 in total

1.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.

Authors:  A Hartmann; S Hunot; P P Michel; M P Muriel; S Vyas; B A Faucheux; A Mouatt-Prigent; H Turmel; A Srinivasan; M Ruberg; G I Evan; Y Agid; E C Hirsch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.

Authors:  Albert Stezin; Rajini M Naduthota; Ragasudha Botta; Shriram Varadharajan; Abhishek Lenka; Jitender Saini; Ravi Yadav; Pramod Kumar Pal
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

Review 3.  Parkinson's disease pathogenesis from the viewpoint of small fish models.

Authors:  Hideaki Matsui; Ryosuke Takahashi
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

4.  DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.

Authors:  Ling-Yang Hao; Benoit I Giasson; Nancy M Bonini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

5.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.

Authors:  Matthew W Bishop; Subhojit Chakraborty; Gillian A C Matthews; Antonios Dougalis; Nicholas W Wood; Richard Festenstein; Mark A Ungless
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

Review 6.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

7.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  Three-dimensional and stereological characterization of the human substantia nigra during aging.

Authors:  Ana Tereza Di Lorenzo Alho; Claudia Kimie Suemoto; Lívia Polichiso; Edilaine Tampellini; Kátia Cristina de Oliveira; Mariana Molina; Glaucia Aparecida Bento Santos; Camila Nascimento; Renata Elaine Paraizo Leite; Renata Eloah de Lucena Ferreti-Rebustini; Alexandre Valotta da Silva; Ricardo Nitrini; Carlos Augusto Pasqualucci; Wilson Jacob-Filho; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  Brain Struct Funct       Date:  2015-09-19       Impact factor: 3.270

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.